Company / Operating Income
Cytokinetics Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$612.3M
FY2025
5-year range
-$612.3M / -$186.3M
FY2021-FY2025
Trend
-14.2%
vs FY2024
Sector context
#191 of 204
Health Care
What the data says
Among 204 Health Care companies, Cytokinetics is in the bottom 6% for operating income. Operating Income has declined for 5 consecutive years, from -$94M in FY2020 to -$612M in FY2025.
Based on SEC 10-K filings.
-$612M in FY2025.
Declined from -$496M to -$612M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 204This company -$612.3M Sector average $107.7M
▼
-668.4% below sector average
Key checks
Key Insights
- Cytokinetics's operating income has declined for 5 consecutive years.
- In FY2025, operating income decreased 14.2% year-over-year.
- Ranks #191 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.12 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$612.3M | -14.2% |
| FY2024 | -$536.2M | -8.1% |
| FY2023 | -$496.2M | -53.1% |
| FY2022 | -$324.2M | -74.0% |
| FY2021 | -$186.3M | -98.3% |
| FY2020 | -$93.9M | +5.0% |
| FY2019 | -$98.9M | -11.2% |
| FY2018 | -$88.9M | +21.6% |
| FY2017 | -$113.4M | -706.8% |
| FY2016 | $18.7M | +150.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026